Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
about
Promising Therapy Candidates for Liver FibrosisNew Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical TrialsManagement of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's LawEpithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compoundsEndothelial dysfunction in cirrhosis: Role of inflammation and oxidative stressPathophysiology of portal hypertensionCancer and liver cirrhosis: implications on prognosis and managementTyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?Clinical Advancements in the Targeted Therapies against Liver Fibrosis.Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.Angiogenesis and liver fibrosisPrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesBevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cellsComplementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway.Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.Future therapy of portal hypertension in liver cirrhosis - a guess.Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure.Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesisSinusoidal obstruction syndrome (hepatic veno-occlusive disease)Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis.Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices.Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure.Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibitionCombination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in ratsRapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway.Thalidomide Improves the Intestinal Mucosal Injury and Suppresses Mesenteric Angiogenesis and Vasodilatation by Down-Regulating Inflammasomes-Related Cascades in Cirrhotic RatsThe chinese herbal decoction danggui buxue tang inhibits angiogenesis in a rat model of liver fibrosis.Ischemia reperfusion of the hepatic artery induces the functional damage of large bile ducts by changes in the expression of angiogenic factors.Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in ratsTargeted therapies for hepatocellular carcinoma.Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activationDeterminants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib.Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats.
P2860
Q26766727-6FC92397-ABCC-49B2-AB0D-63422FA2E08BQ26772800-4E12D068-C518-4E50-9EE9-84CD99773083Q26797581-85874C9F-035A-475C-8438-5D51C4E64A89Q27013565-A24067AA-B895-46C4-9D89-BD4816C884F9Q27023122-BE66A74A-0DAD-4200-AA51-9A184721619DQ27026406-B60FCC41-47E8-4D32-8E26-38B3BD6EAE8BQ28068579-1AE742ED-B73E-4A28-8FFD-C975B7B27C7DQ28068710-B9CCB0E2-E3AA-46D1-8FB7-A2F3FCCEA900Q28078684-25A6DF93-BF98-45DA-9653-AB517B56751EQ28082065-0F5A3509-EBA4-4C51-ADF2-7EA0AFB2EAC8Q28082569-BA492E42-CE5D-468D-84B5-E9B3A51FAB21Q28272678-3E8BFC73-BAB5-4637-8A15-B2E3027DCA6DQ28536257-B5AA4F5F-A741-440D-AED5-AB44538E63A9Q30465168-FF4E134D-6FF7-4007-90CE-6277BB6C73EDQ33702040-33E8336F-E9A7-4398-BCF9-80EF84F1D64FQ33826258-AA5E7B06-AC99-4515-8AF3-9E3AD103D42AQ34321931-8CAE61CD-260C-4A8C-B038-BAF2CD1E4DADQ34352802-F7891557-47A4-457A-9642-EDB44974E374Q34446521-4603435E-56E9-4A84-862C-2253CACFDBB6Q34558284-67F3C5E3-FA21-4897-BDFD-DDE3D2D3EB8EQ34902424-858854F2-33CA-4922-89C4-1620D2CEEBE7Q34983459-194ED264-9D23-4B53-890B-6267A80A59A3Q35131876-4FE3DB5A-257C-4D5C-B01F-3D01AF70487AQ35136411-8D181FC7-80BD-4FBF-A5AA-0CFD22C2293AQ35154961-FF0D9991-5D97-4A94-87DB-7658109D3B42Q35541817-E61FA0A6-E88A-4715-8C9F-B875B7544825Q35560583-5FDA843E-60E4-4416-A7FF-663804BEE183Q35651447-503BAEA0-25EA-46F0-B13A-9CB9CACFC0C4Q35740334-55C061D0-E459-4E91-A595-A3BF17C1C5CEQ35842553-642CBE5D-6691-4778-B690-C7B9DA6882E5Q35886555-E714C69F-93F0-4DF5-894A-EE9B77DF0B1AQ35906919-69AB28A9-331F-464C-9667-6A6369A36499Q36180467-FB945D5C-65A3-429D-99B8-EF3C9B066094Q36345910-9519BAE8-F5C2-4DBA-BDD2-038E5492DC28Q36625697-ED1A99B7-84FF-4A1D-8CCB-9C84603299EAQ36746393-A3B71F65-3659-4F58-9B55-EC10DB9778E7Q36928888-419F0E14-C23F-43AF-9D72-F97989BDD28BQ36973713-AAE973CA-79D7-4712-9186-51F14BD86938Q37045749-E951CE78-6FFB-4214-A9AE-3C09E249277FQ37262768-D0B512C7-EF26-4F49-A1D3-CCEA11F15721
P2860
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.
@en
Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.
@nl
type
label
Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.
@en
Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.
@nl
prefLabel
Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.
@en
Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.
@nl
P2093
P2860
P356
P1433
P1476
Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.
@en
P2093
Carolina Tiani
Ester Garcia-Pras
Jaime Bosch
Marc Mejias
Mercedes Fernandez
Rosa Miquel
P2860
P304
P356
10.1002/HEP.22758
P407
P577
2009-04-01T00:00:00Z